The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
This early-phase study assessed sonrotoclax (an investigational BCL2 inhibitor) with carfilzomib and dexamethasone in 20 patients with relapsed/refractory multiple myeloma with a genetic rearrangement subtype t(11;14). In the 19 patients whose response could be evaluated, the overall response rate (ORR) was 84%, which included 32% of patients with a complete response or stringent complete response, with a median time to response of 1 month. The treatment combination was generally well tolerated. Most side effects were manageable. The most common all-grade treatment-emergent adverse events (TEAEs) were insomnia, fatigue, nausea, anemia, and back pain, but none led to death. Four patients died during the study, all for reasons unrelated to the study treatments. Enrollment in the BGB-11417-105 study is ongoing, and additional treatment combinations with sonrotoclax are being investigated.
